Evidence map›Paper›PMID 36066557›Full record

Trial reportEuropean journal of heart failure2022

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.

Adriaan A Voors, Kevin Damman, John R Teerlink, Christiane E Angermann, Sean P Collins, Mikhail Kosiborod, Jan Biegus, João Pedro Ferreira, Michael E Nassif, Mitchell A Psotka and 6 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 6 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 6 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Observational
  10. Review
  11. Review
  12. 2024 update in heart failure.ESC heart failure · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 8 countries.

Adriaan A VoorsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Kevin DammanDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
John R TeerlinkSection of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
Christiane E AngermannComprehensive Heart Failure Centre, University & University Hospital of Würzburg, Würzburg, Germany.
Sean P CollinsDepartment of Emergency Medicine, Vanderbilt University Medical Center and Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center, Nashville, TN, USA.
Mikhail KosiborodSaint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MS, USA.
Jan BiegusInstitute of Heart Diseases, Medical University, Wroclaw, Poland.
João Pedro FerreiraInserm INI-CRCT, CHRU, Université de Lorraine, Nancy, France.
Michael E NassifSaint Luke's Mid America Heart Institute and the University of Missouri, Kansas City, MS, USA.
Mitchell A PsotkaInova Heart and Vascular Institute, Falls Church, VA, USA.
Jasper TrompSaw Swee Hock School of Public Health, National University of Singapore, and the National University Health System, Singapore.
Martina BrueckmannBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Jonathan P BlatchfordElderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Afshin SalsaliBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
Piotr PonikowskiInstitute of Heart Diseases, Medical University, Wroclaw, Poland.
EMPULSE Trial Investigators
Boehringer Ingelheim (Germany) · DEUniversity Medical Center Groningen · NLWroclaw Medical University · PLAlaska Heart and Vascular Institute · USNational University of Singapore · SGRutgers, The State University of New Jersey · USSaint Luke's Hospital · USUniversidade do Porto · PTUniversitätsklinikum Würzburg · DEUniversity of California, San Francisco · USUniversity of Missouri–Kansas City · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In patients with chronic heart failure, SGLT2 inhibitors cause an early decline in estimated glomerular filtration rate (eGFR) followed by a slower eGFR decline over time than placebo. However, the effects of SGLT2 inhibitors on renal function during a hospital admission for acute heart failure remain largely unknown. METHODS AND

resultsBetween 1 and 5 days after a hospitalization for acute heart failure, 530 patients with an eGFR >20 ml/min/1.73 m

conclusionIn patients hospitalized for acute heart failure, empagliflozin caused an early modest decline in renal function which was no longer evident after 90 days. Acute renal events were similar in both groups. The clinical benefit of empagliflozin was consistent regardless of baseline renal function.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosidesHospitalizationHumansKidneyQuality of LifeBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsAcute heart failureChronic kidney diseaseRenal functionSGLT2 inhibitor

Identifiers

PMID36066557
PMCPMC9828037
OpenAlexW4294817235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.